I have a novice question:
If for AML the company can use RC110 and then bridge to RC220 when it becomes available why the same approach can’t be taken for mBC? That could have us running mBC trials in the clinic now and have additional data with RC220 and show that both RC110 and RC220 have similar outcomes in terms of safety and efficacy which would chop one year off the clinical trial start and hence final transaction.
Ann: Race Strategic Update August 2023, page-77
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.010(0.57%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| $1.73 | $1.83 | $1.73 | $272.0K | 152.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9998 | $1.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |